Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.
Kirtane AJ, Généreux P, Lewis B, Shlofmitz RA, Dohad S, Choudary J, Dahle T, Pineda AM, Shunk K, Maehara A, Popma A, Redfors B, Ali ZA, Krucoff M, Armstrong E, Kandzari DE, O'Neill W, Kraemer C, Stiefel KM, Jones DE, Chambers J, Stone GW; ECLIPSE Investigators.
Lancet. 2025 Apr 12;405(10486):1240-1251. doi: 10.1016/S0140-6736(25)00450-7. Epub 2025 Mar 30.
Prognostic value of plasma pentraxin-3 levels in patients with stable coronary artery disease after drug-eluting stent implantation.
Haibo L, Xiaofang G, Chunming W, Jie Y, Guozhong C, Limei Z, Yong C, Yu F, Yingchun B, Wangjun Y, Junbo G.
Mediators Inflamm. 2014;2014:963096. doi: 10.1155/2014/963096. Epub 2014 Nov 24.
Individual patient data meta-analysis of paclitaxel-coated balloons vs. drug-eluting stents for small-vessel coronary artery disease: the ANDROMEDA study.
Fezzi S, Giacoppo D, Fahrni G, Latib A, Alfonso F, Colombo A, Mahfoud F, Scheller B, Jeger R, Cortese B.
Eur Heart J. 2025 May 2;46(17):1586-1599. doi: 10.1093/eurheartj/ehaf002.
Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
Tiroch K, Mehilli J, Byrne RA, Schulz S, Massberg S, Laugwitz KL, Vorpahl M, Seyfarth M, Kastrati A; ISAR-LEFT MAIN Study Investigators.
JACC Cardiovasc Interv. 2014 Jan;7(1):29-36. doi: 10.1016/j.jcin.2013.08.013. Epub 2013 Dec 11.
Validation of complex PCI criteria in drug-coated balloon angioplasty.
Tartaglia F, Gitto M, Leone PP, Chiarito M, Calamita G, Mincione G, Gasparini G, Reimers B, Cozzi OF, Rossi ML, Stefanini GG, Regazzoli D, Mangieri A, Colombo A.
Clin Res Cardiol. 2025 Aug;114(8):1059-1070. doi: 10.1007/s00392-025-02664-x. Epub 2025 May 19.
One-year clinical results and total costs of drug-eluting stents implantation in multivessel coronary artery disease.
Varani E, Balducelli M, Vecchi G, Aquilina M, Maresta A.
J Cardiovasc Med (Hagerstown). 2007 Aug;8(8):596-601. doi: 10.2459/JCM.0b013e32801051f4.
Mid-term clinical outcomes of new generation drug-eluting stents for treatment of diffuse coronary artery disease.
Çoner A, Çiçek D, Akıncı S, Balcıoğlu S, Altın C, Müderrisoğlu H.
Turk Kardiyol Dern Ars. 2018 Dec;46(8):659-666. doi: 10.5543/tkda.2018.10.5543/tkda.2018.62678.
Effectiveness and Safety of Zotarolimus-Eluting Stent (Resolute Integrity) in Patients with Diffuse Long Coronary Artery Disease.
Park KH, Ahn Y, Koh YY, Ki YJ, Kim SS, Kim HK, Choi DH, Hong YJ, Hwang JY, Kim DH, Rhew JY, Ryu JK, Park JS, Park TH, Yang TH, Oh SK, Lee BR, Lee SU, Lee SG, Chun KJ, Cho JH, Cha KS, Chae JK, Hur SH, Hwang SH, Park HS, Kim DI.
Korean Circ J. 2019 Aug;49(8):709-720. doi: 10.4070/kcj.2019.0018. Epub 2019 May 15.
Short-term follow-up results of drug-eluting stenting in premature coronary artery disease patients with multiple atherosclerotic risk factors.
Wang MH, Lee WL, Wang KY, Hsieh YC, Liu TJ, Lin IH, Lin WW, Ting CT, Liang KW.
J Chin Med Assoc. 2008 Jul;71(7):342-6. doi: 10.1016/S1726-4901(08)70136-9.
Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).
Schofer J, Schlüter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G; E-SIRIUS Investigators.
Lancet. 2003 Oct 4;362(9390):1093-9. doi: 10.1016/S0140-6736(03)14462-5.
